Madrigal Pharmaceuticals stock drops over 8% after whistleblower complaint disclosure
AI Summary- Madrigal disclosed a whistleblower complaint alleging issues with Rezdiffra safety and efficacy reporting.
- Madrigal's stock price fell over 8% after the complaint became public.
- The complaint was filed October 9, 2026, and disclosed in Madrigal's November 3 quarterly report.